AU2017222644B2 - Novel vaccines against Zika virus - Google Patents

Novel vaccines against Zika virus Download PDF

Info

Publication number
AU2017222644B2
AU2017222644B2 AU2017222644A AU2017222644A AU2017222644B2 AU 2017222644 B2 AU2017222644 B2 AU 2017222644B2 AU 2017222644 A AU2017222644 A AU 2017222644A AU 2017222644 A AU2017222644 A AU 2017222644A AU 2017222644 B2 AU2017222644 B2 AU 2017222644B2
Authority
AU
Australia
Prior art keywords
zikv
prme
zika
mice
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017222644A
Other languages
English (en)
Other versions
AU2017222644A1 (en
Inventor
Karuppiah Muthumani
David Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
The Wistar Institute
Original Assignee
University of Pennsylvania
The Wistar Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania, The Wistar Institute filed Critical University of Pennsylvania
Publication of AU2017222644A1 publication Critical patent/AU2017222644A1/en
Application granted granted Critical
Publication of AU2017222644B2 publication Critical patent/AU2017222644B2/en
Priority to AU2021258056A priority Critical patent/AU2021258056B2/en
Priority to AU2024204641A priority patent/AU2024204641A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017222644A 2016-02-25 2017-02-24 Novel vaccines against Zika virus Active AU2017222644B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021258056A AU2021258056B2 (en) 2016-02-25 2021-10-29 Novel vaccines against Zika virus
AU2024204641A AU2024204641A1 (en) 2016-02-25 2024-07-04 Novel vaccines against Zika virus

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300030P 2016-02-25 2016-02-25
US62/300,030 2016-02-25
US201662305183P 2016-03-08 2016-03-08
US62/305,183 2016-03-08
US201662396742P 2016-09-19 2016-09-19
US62/396,742 2016-09-19
US201662417100P 2016-11-03 2016-11-03
US62/417,100 2016-11-03
US201762462249P 2017-02-22 2017-02-22
US62/462,249 2017-02-22
PCT/US2017/019407 WO2017147458A1 (en) 2016-02-25 2017-02-24 Novel vaccines against zika virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021258056A Division AU2021258056B2 (en) 2016-02-25 2021-10-29 Novel vaccines against Zika virus

Publications (2)

Publication Number Publication Date
AU2017222644A1 AU2017222644A1 (en) 2018-09-13
AU2017222644B2 true AU2017222644B2 (en) 2021-07-29

Family

ID=59685658

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017222644A Active AU2017222644B2 (en) 2016-02-25 2017-02-24 Novel vaccines against Zika virus
AU2021258056A Active AU2021258056B2 (en) 2016-02-25 2021-10-29 Novel vaccines against Zika virus
AU2024204641A Pending AU2024204641A1 (en) 2016-02-25 2024-07-04 Novel vaccines against Zika virus

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021258056A Active AU2021258056B2 (en) 2016-02-25 2021-10-29 Novel vaccines against Zika virus
AU2024204641A Pending AU2024204641A1 (en) 2016-02-25 2024-07-04 Novel vaccines against Zika virus

Country Status (10)

Country Link
US (2) US11648303B2 (enExample)
EP (1) EP3419660A4 (enExample)
JP (3) JP7012365B2 (enExample)
KR (1) KR20190003471A (enExample)
CN (2) CN109152826B (enExample)
AU (3) AU2017222644B2 (enExample)
BR (1) BR112018017307A2 (enExample)
CA (1) CA3015792A1 (enExample)
MX (2) MX2018010291A (enExample)
WO (1) WO2017147458A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
KR20190003471A (ko) 2016-02-25 2019-01-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 지카 바이러스에 대항하는 신규한 백신
US11666649B2 (en) * 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
MY202505A (en) 2017-11-03 2024-05-01 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003975WA (en) 2017-11-30 2020-06-29 Takeda Vaccines Inc Method for inactivating zika virus and related methods
US11491217B2 (en) 2017-12-06 2022-11-08 Emory University Chimeric viruses encoding mutant zika virus envelope glycoproteins
US11738079B2 (en) 2018-07-23 2023-08-29 The University Of Adelaide Zika virus vaccine
WO2020092564A1 (en) * 2018-10-31 2020-05-07 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
KR102553857B1 (ko) * 2021-02-05 2023-07-17 에스티팜 주식회사 신규 핵산 분자

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292453A1 (en) * 2005-12-14 2007-12-20 Floyd Robert A RNA virus vaccines and methods
US8691961B1 (en) * 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2017015463A2 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014245A1 (en) * 1998-09-02 2000-03-16 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Dengue viruses that are replication defective in mosquitos for use as vaccines
JP5788676B2 (ja) * 2008-01-11 2015-10-07 イノビオ ファーマシューティカルズ，インコーポレイティド デングウイルスの複数のサブタイプに対する新規ワクチン
CA3001374A1 (en) * 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
KR20120093163A (ko) * 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
BR112012010357B1 (pt) * 2009-11-02 2022-05-24 Inovio Pharmaceuticals, Inc. Proteínas de consenso de vírus de doença de febre aftosa (fmdv), sequências de codificação para as mesmas e vacinas feitas a partir das mesmas
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
BR112012024224A2 (pt) * 2010-03-24 2016-11-29 Arbovax Inc mutações da faixa de hospedeiro de flavivírus e seu uso.
CN103476928B (zh) * 2010-12-09 2017-03-29 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
CA2826199A1 (en) 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EP2788478B1 (en) 2011-12-09 2017-08-23 Institut Pasteur Multiplex immuno screening assay
US9987347B2 (en) * 2013-03-15 2018-06-05 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of dengue virus
CA2992531C (en) 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017140905A1 (en) * 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
KR20190003471A (ko) * 2016-02-25 2019-01-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 지카 바이러스에 대항하는 신규한 백신
MX2019000725A (es) * 2016-07-18 2019-07-04 Variation Biotechnologies Inc Composiciones de vacuna para tratamiento de virus zika.
KR102668318B1 (ko) * 2016-09-19 2024-05-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 지카바이러스에 대항하는 신규한 백신 및 지카바이러스에 대해 사용하기 위한 dna 항체 작제물의 조합
EP3568155A4 (en) * 2017-01-11 2020-09-23 The Trustees Of The University Of Pennsylvania RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292453A1 (en) * 2005-12-14 2007-12-20 Floyd Robert A RNA virus vaccines and methods
US8691961B1 (en) * 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2017015463A2 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines

Also Published As

Publication number Publication date
AU2021258056B2 (en) 2024-04-04
CA3015792A1 (en) 2017-08-31
US20240115689A1 (en) 2024-04-11
AU2021258056A1 (en) 2021-11-25
BR112018017307A2 (pt) 2019-01-08
JP2024096281A (ja) 2024-07-12
JP2019506175A (ja) 2019-03-07
CN109152826A (zh) 2019-01-04
KR20190003471A (ko) 2019-01-09
MX2023006203A (es) 2023-06-12
JP7012365B2 (ja) 2022-03-04
JP2022023241A (ja) 2022-02-07
EP3419660A4 (en) 2019-11-06
US11648303B2 (en) 2023-05-16
AU2017222644A1 (en) 2018-09-13
US20210315987A1 (en) 2021-10-14
CN109152826B (zh) 2022-11-04
WO2017147458A1 (en) 2017-08-31
JP7555325B2 (ja) 2024-09-24
EP3419660A1 (en) 2019-01-02
AU2024204641A1 (en) 2024-07-25
US12419945B2 (en) 2025-09-23
CN115927399A (zh) 2023-04-07
MX2018010291A (es) 2019-06-06

Similar Documents

Publication Publication Date Title
AU2021258056B2 (en) Novel vaccines against Zika virus
US20240131154A1 (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
JP5744719B2 (ja) チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
US20190091322A1 (en) Dna antibody constructs and method of using same
US20110262394A1 (en) Dna constructs eliciting immune response against flavivirus and effective adjuvants
KR20110082566A (ko) 개량된 ｈｃｖ 백신 및 이를 이용하는 방법
US20180326037A1 (en) Novel Vaccines Against Multiple Subtypes Of Dengue Virus
EP2968394A1 (en) Novel vaccines against multiple subtypes of dengue virus
HK40091502A (en) Novel vaccines against zika virus

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO ADD CO-APPLICANT THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

FGA Letters patent sealed or granted (standard patent)